Scott Platshon

Scott Platshon is a Partner at EcoR1 Capital, LLC, a biotechnology-focused investment firm based in San Francisco, which he joined in 2015. He has played a significant role in the firm, serving on the Board of Directors for several companies, including Ajax Therapeutics and Kumquat Biosciences, and as a board observer for others like PellePharm and Ashvattha Therapeutics.123

Education and Early Career

Platshon holds a Bachelor of Science in Bioengineering from Stanford University, where he also participated in varsity water polo.2 Before joining EcoR1, he worked as a financial analyst at Aquilo Partners, a boutique investment bank specializing in life sciences.13

Professional Contributions

In his current role at EcoR1 Capital, Platshon is involved in strategic investment decisions and operational leadership within the biotechnology sector. His expertise has contributed to the growth and success of various companies in the industry.4 He has also held leadership roles in other organizations, including serving as Chief Operating Officer at Panacea Acquisition Corporation I & II from July 2020 to May 2023.3

Skills and Interests

Platshon is recognized for his operational and strategic leadership capabilities in healthcare and biotechnology, and he has a keen interest in advancing innovative solutions within these fields. He is also proficient in Japanese at an elementary level, alongside his native English.3